✦ LIBER ✦

Irbesartan safety and effectiveness: a post-marketing surveillance study

✍ Scribed by HE Bays; JS Park; K Reilly; J Triscari

Book ID: 117605759
Publisher: Nature Publishing Group
Year: 1999
Tongue: English
Weight: 131 KB
Volume: 12
Category: Article
ISSN: 0895-7061
DOI: 10.1016/s0895-7061(99)80421-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Post marketing surveillance of 13 produc

Post marketing surveillance of 13 products: safety and effectiveness

✍ Kazuko Yoshioka; Akira Kosasayama; Mika Yoshida; Miki Toshikura; Kunihisa Nasu; 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB

A Post-Marketing Surveillance Study of F

A Post-Marketing Surveillance Study of Formoterol (Foradil®)1

✍ Dr Lynda V. Wilton, Saad A. Shakir 📂 Article 📅 2002 🏛 Springer International Publishing AG 🌐 English ⚖ 145 KB

Post-marketing surveillance or drug acce

Post-marketing surveillance or drug acceptability study? [editorial]

✍ DB Barnett; KL Woods 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 277 KB

Tolerability and safety of donepezil in

Tolerability and safety of donepezil in the treatment of Alzheimer's disease: results from a Post Marketing Surveillance study

✍ C.A. Sramko; F. Berger; P. Calabrese; L. Frölich 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 150 KB

Safety and effectiveness responses to et

Safety and effectiveness responses to etanercept for rheumatoid arthritis in Japan: a sub-analysis of a post-marketing surveillance study focusing on the duration of rheumatoid arthritis

✍ Koike, Takao; Harigai, Masayoshi; Inokuma, Shigeko; Ishiguro, Naoki; Ryu, Junnos 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 416 KB

The safety of risperidone: a post-market

The safety of risperidone: a post-marketing study on 7684 patients

✍ F. J. Mackay; L. V. Wilton; G. L. Pearce; S. N. Freemantle; R. D. Mann 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB 👁 1 views

Risperidone is a relatively new antipsychotic agent licensed for the treatment of schizophrenia and other psychotic conditions in patients aged 15 years or older. This study examines the safety of risperidone used in general practice. Information was collected for 7684 patients included in a non-int